Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is characterized by uncontrolled cell division, making cell cycle regulators like cyclin-dependent kinases (CDKs) critical therapeutic targets.
• While CDK inhibitors (CDKIs) are approved for certain cancers, first-generation pan-CDK inhibitors faced challenges due to toxicity and lack of specificity.
• Recent advancements in combination therapy have shown potential in mitigating the adverse effects of pan-CDK inhibitors.

Purpose of the Study:

• To review the members of the CDK family and their roles in cell cycle regulation.
• To provide an overview of the current research landscape for CDK inhibitors.
• To highlight the renewed potential of pan-CDK inhibitors in combination therapy for cancer treatment.

Main Methods:

• Literature review of CDK family members and their functions in cell cycle regulation.
• Review of existing studies on various CDK inhibitors, including first-generation pan-CDK inhibitors.
• Analysis of recent advancements in combination therapy strategies involving CDK inhibitors.

Main Results:

• Cyclin-dependent kinases (CDKs) are central regulators of the cell cycle, making them key targets in cancer therapy.
• First-generation pan-CDK inhibitors demonstrated significant toxicity and lack of selectivity, limiting their clinical application.
• Emerging combination therapy approaches have successfully reduced the toxicity of pan-CDK inhibitors, enhancing their therapeutic potential.

Conclusions:

• Pan-CDK inhibitors, when used in combination regimens, offer renewed promise for clinical application in cancer treatment.
• Further research into optimizing combination therapies is crucial for maximizing the efficacy and safety of CDK inhibitors.
• Understanding CDK family roles is essential for developing targeted cancer therapies.